Novartis and Aster sign an MoU to advance digital transformation and clinical research
- The collaboration focuses on digital transformation and clinical research
- Novartis will provide its expertise and share best practices and enable data generation, ideation, and impactful decision making for Aster DM Healthcare’s clinical research program
The collaboration focused on digital transformation and clinical research will aim to identify current gaps in patient care and introduce extensive medical programmes using innovative data platforms and data syndicated designs. This is in alignment with Aster’s long-term plan to integrate clinical research and digital transformation into its operations in UAE and beyond which will have a significant impact on the clinical outcome delivery for patients.
As a part of the collaboration, Novartis will enable data generation, ideation, and impactful decision making for Aster DM Healthcare’s clinical research program. The organizations have plans to initiate a series of workshops, trainings, and educational activities, which will assist Aster to commence its activities on clinical research.
The digital transformation initiatives will also separately work on boosting the digital healthcare strategy of Aster DM Healthcare for its market in UAE and beyond, whereas Novartis will provide its expertise and share best practices.
“Data Analytics with focus on clinical research is one of the cornerstones of healthcare in future. Aster tries to stay ahead of the curve in offering the best medical solutions to our patients and equip our doctors with the most advanced systems to be able to do so. We have associated with Novartis in the past and are glad to enter into a multi-faceted partnership to enhance Digital Transformation and Research,” said Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare.
Novartis a leading global medicines company, utilizes innovation science and digital technologies to develop transformative treatments in areas of urgent medical need and will continue to reimagine medicine to improve and extend people’s lives.
“At Novartis, we are committed to building new partnerships as part of our efforts to improve access to quality healthcare. Aster DM Healthcare is a valuable partner for us in this journey. We truly believe that we share a common vision, and we are confident that this partnership has the potential to add value and have an impact on patients in UAE. We are happy to collaborate with Aster to realize their vision towards data transformation and clinical research, both of which are tantalizing growth areas for the healthcare sector,” said Mohamed Ezz Eldin, President and Head of Gulf Cluster, Novartis Pharmaceuticals.
